Paper · 39413197
Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming.
Thielman NRJ and 18 others. Sci Adv, 2024. Cited by 17 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. Papers, record 39413197. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39413197
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Pancreatic Ductal | Major topic |
| Disease Progression | Major topic |
| Macrophages | Major topic |
| Neoplasm Metastasis | Major topic |
| Pancreatic Neoplasms | Major topic |
| Semaphorins | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Cell Line, Tumor | |
| Cellular Reprogramming | |
| Disease Models, Animal | |
| Proto-Oncogene Proteins p21(ras) |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA006973 | NCI NIH HHS | United States | P30CA006973 | PubMed | NIH RePORTER |
| R01 CA169702 | NCI NIH HHS | United States | R01CA169702 | PubMed | NIH RePORTER |
| R01 CA197296 | NCI NIH HHS | United States | R01CA197296 | PubMed | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 37,961,340 | Tumor- and Nerve-Derived Axon Guidance Molecule Promotes Pancreatic Ductal Adenocarcinoma Progression and Metastasis through Macrophage Reprogramming. | https://conductscience.org/library/papers/37961340 |
Source PubMed
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19,016,445 | The isolation and characterization of murine macrophages. | Curr Protoc Immunol | 2008 | https://conductscience.org/library/papers/19016445 | PubMed |
| 2 | 12,406,905 | CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. | Blood | 2003 | https://conductscience.org/library/papers/12406905 | PubMed |
| 3 | 28,315,433 | Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. | Cancer Lett | 2017 | https://conductscience.org/library/papers/28315433 | PubMed |
| 4 | 28,049,847 | Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28049847 | PubMed |
| 5 | 35,902,743 | Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. | Nat Genet | 2022 | https://conductscience.org/library/papers/35902743 | PubMed |
| 6 | 25,285,458 | A preclinical murine model of hepatic metastases. | J Vis Exp | 2014 | https://conductscience.org/library/papers/25285458 | PubMed |
| 7 | 30,577,767 | Semaphorin-5A maintains epithelial phenotype of malignant pancreatic cancer cells. | BMC Cancer | 2018 | https://conductscience.org/library/papers/30577767 | PubMed |
| 8 | 27,911,862 | Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. | Oncotarget | 2016 | https://conductscience.org/library/papers/27911862 | PubMed |
| 9 | 25,590,802 | Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling. | Cell Death Dis | 2015 | https://conductscience.org/library/papers/25590802 | PubMed |
| 10 | 26,393,880 | MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC. | Oncotarget | 2015 | https://conductscience.org/library/papers/26393880 | PubMed |
1 to 10 of 60
See all 60 referencesCited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,880,979 | Neuro-associated SEMA3C+ tumour cells promote gastric cancer peritoneal metastasis via EBF2-FGF7-FGFR2-mediated tumour-endothelial crosstalk. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42880979 | PubMed |
| 42,782,738 | Biomarker-Driven Strategies for Stromal Reprogramming in Pancreatic Ductal Adenocarcinoma. | Cells | 2026 | https://conductscience.org/library/papers/42782738 | PubMed |
| 42,703,620 | KRAS-driven cytokine-metabolic crosstalk shapes immune exclusion in pancreatic ductal adenocarcinoma. | Front Genet | 2026 | https://conductscience.org/library/papers/42703620 | PubMed |
| 42,565,215 | The tumor microenvironment in pancreatic cancer: from composition to therapeutic targeting. | Biochem Soc Trans | 2026 | https://conductscience.org/library/papers/42565215 | PubMed |
| 42,447,338 | Variational sparse Gaussian-process method for detecting spatially variable genes and cellular interactions in spatial transcriptomics. | Brief Bioinform | 2026 | https://conductscience.org/library/papers/42447338 | PubMed |
| 41,969,468 | Individualized treatment and key prognostic biomarkers based on folate metabolism in patients with pancreatic cancer. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/41969468 | PubMed |
| 41,545,706 | Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/41545706 | PubMed |
| 41,459,510 | Macrophage polarization: molecular mechanisms, disease implications, and targeted therapeutic strategies. | Front Immunol | 2025 | https://conductscience.org/library/papers/41459510 | PubMed |
| 41,163,091 | Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies. | Mil Med Res | 2025 | https://conductscience.org/library/papers/41163091 | PubMed |
| 41,009,819 | Tumor Innervation: From Bystander to Emerging Therapeutic Target for Cancer. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41009819 | PubMed |
1 to 10 of 13
See all 13 cited byGenes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SEMA3D | 223,117 | PubTator's text mining | https://conductscience.org/library/genes/223117 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39413197
GET https://conductscience.org/api/papers/v1/39413197/references?page=2